Angioplasty News and Research

RSS

In angioplasty procedures, a balloon is fed through a catheter and used to prop open an artery that has become narrowed or blocked. In cases where stenting is appropriate, a stent mounted on a balloon is inserted and inflation of the balloon expands the stent against the blocked artery wall to hold the vessel open. The balloon is then deflated and the catheter is withdrawn. Stent treatment of arteries holds them open and improves blood flow to the heart. In cases where post-dilatation is needed, a high-pressure balloon is inflated inside a stent to help better place the stent against the vessel wall.

ART's stent superior than other bioresorbable stents

Arterial Remodeling Technologies disclosed today new data related to its bioresorbable stent platform—additional data that further validates the Company's innovative approach to simultaneously balance biocompatibility, biomechanics and bioresorption within a bioresorbable PLA (polylactic acid) stent.

8 Dec 2010

Sheathless transradial intervention highly successful in treating complex lesions

Cardiologists from the Mayo Clinic performed sheathless transradial percutaneous coronary intervention (PCI) to remedy complex lesions, achieving a 90% success rate with no radial complications. Standard guiding catheters were used during the procedure. Details of this novel approach—overcoming the last hurdle to greater adoption of transradial PCI in the U.S.—are published in the December issue of Catheterization and Cardiovascular Intervention, the official journal of The Society for Cardiovascular Angiography and Interventions.

7 Dec 2010

Cardiologists achieve 90% success rate in sheathless transradial PCI to remedy complex lesions

7 Dec 2010

FDA approves IDE application to initiate Tryton Side Branch Stent System for coronary artery disease

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced U.S. Food and Drug Administration (FDA) conditional approval for an Investigational Device Exemption (IDE) application to initiate the pivotal trial to evaluate the Tryton Side Branch Stent System for the treatment of coronary artery disease.

2 Dec 2010

Interventional Radiology physician utilizes SUPERA VERITAS system to treat biliary stricture

IDEV Technologies, Incorporated, an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced the first procedure in the United States utilizing the SUPERA VERITAS Transhepatic Biliary System, which was recently cleared to market by the U.S. Food and Drug Administration.

30 Nov 2010

Scott & White Healthcare’s Cardiac Rehabilitation Program receives AACVPR accreditation

The Cardiac Rehabilitation Program at Scott & White Healthcare in Temple has received accreditation from the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR).

24 Nov 2010

Treatment including surgery better for opening blocked arteries in patients with diabetes and heart disease

Treatment that included early surgical procedures to open blocked arteries resulted in better blood flow to the heart than aggressive medical treatment alone in patients with both diabetes and heart disease, according to a study presented at the American Heart Association's Scientific Sessions 2010.

17 Nov 2010

SESAME Stent effective for patients undergoing angioplasty of SVG

A new study revealed that the novel self-expanding super-elastic all-metal endoprosthesis stent (SESAME Stent) used in patients undergoing angioplasty of degenerated saphenous vein graft (SVG) lesions has 100% acute success, low 30 day major adverse cardiac events (MACE) rates, and 9-month patency comparable to balloon expandable stents without embolic protection.

17 Nov 2010

John Muir Health opens The Hofmann Family Patient Care Tower

Today, John Muir Health opened the doors of The Hofmann Family Patient Care Tower at John Muir Medical Center, Concord, which includes 120 new private rooms (61 open with 59 shelled for future use), a new Cardiovascular Institute and a new Emergency Department. The 172,000 square foot facility, which took three years and $212 million to complete, also features state-of-the-art technology and a patient-focused, healing environment.

17 Nov 2010

Novel heart attack treatment results presented at premier USA cardiology forum

Regenerative medicine company Mesoblast Limited (ASX:MSB; USADR:MBLTY) has announced that positive preclinical trial results were presented at the American Heart Association’s annual conference in Chicago showing that the company’s proprietary “off-the-shelf” stem cells can be injected simply, safely, and effectively into the coronary arteries after a heart attack to prevent heart failure.

15 Nov 2010

Medtronic Eureka medical technology innovation portal launched

Medtronic today launched Medtronic Eureka, a European web-based portal for medical technology innovation designed to help physicians and medical technology inventors to bring their innovative ideas to life.

15 Nov 2010

Job strain can increase risk of cardiovascular disease in women

Women who report having high job strain have a 40 percent increased risk of cardiovascular disease, including heart attacks and the need for procedures to open blocked arteries, compared to those with low job strain, according to research presented at the American Heart Association's Scientific Sessions 2010.

14 Nov 2010

People with anxiety disorders require additional cardiac test: Study

People affected by anxiety and depression should receive an additional cardiac test when undergoing diagnosis for potential heart problems, according to a new study from Concordia University, the Universit- du Qu-bec - Montr-al and the Montreal Heart Institute.

12 Nov 2010

Hospitals need to work more to prevent heart attack deaths: Study

Door-to-balloon time has dropped dramatically as hospitals rush heart attack patients into treatment, but a five-year study released Monday shows quicker hospital care has not saved more lives.

10 Nov 2010

Angiotech reports $59.0 million total revenue for third quarter 2010

Angiotech Pharmaceuticals, Inc. today announced that it had released its financial results for the third quarter ended September 30, 2010.

9 Nov 2010

Pervasis receives $920,000 in grants under QTDP program

Pervasis Therapeutics, Inc. today announced that it has been awarded over $920,000 in grants through the U.S. government's Qualifying Therapeutic Discovery Project, which provides tax credits and grants to projects that show significant potential to produce new therapies, reduce long-term health care costs, or significantly advance the goal of curing cancer within the next 30 years.

8 Nov 2010

Novel drug-coated balloon technology adopted in niche applications across Europe: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, novel drug-coated balloon technology is being adopted in niche applications throughout Europe. This market will continue to grow as physicians increasingly use the technology in cases where other devices may not be suitable.

4 Nov 2010

Loyola University surgeon uses new technique to reopen blockages in coronary arteries

In some heart patients, coronary arteries become so clogged that they are difficult or impossible to reopen with conventional balloon angioplasties. Dr. John Lopez of Loyola University Health System is using a new angioplasty technique to reopen these tough blockages by going through the "back door." The technique, called retrograde recanalization, was developed in Japan and is beginning to catch on in centers with advanced expertise in cardiac catheterization.

4 Nov 2010

IDEV receives FDA marketing clearance for SUPERA VERITAS Transhepatic Biliary System

IDEV Technologies, Incorporated (IDEV), an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance to market the SUPERA VERITAS Transhepatic Biliary System.

3 Nov 2010

CYP2C19 gene variant can increase risk of cardiovascular events in patients treated with clopidogrel

An analysis of data from previously published studies indicates that use of the antiplatelet drug clopidogrel for patients who have common genetic variants of a certain gene and are undergoing a procedure such as coronary stent placement have an associated increased risk for major adverse cardiovascular events, particularly development of blood clots in stents, according to a study in the October 27 issue of JAMA.

27 Oct 2010

Angioplasty News and Research

ART's stent superior than other bioresorbable stents

Sheathless transradial intervention highly successful in treating complex lesions

Cardiologists achieve 90% success rate in sheathless transradial PCI to remedy complex lesions

FDA approves IDE application to initiate Tryton Side Branch Stent System for coronary artery disease

Interventional Radiology physician utilizes SUPERA VERITAS system to treat biliary stricture

Scott & White Healthcare’s Cardiac Rehabilitation Program receives AACVPR accreditation

Treatment including surgery better for opening blocked arteries in patients with diabetes and heart disease

SESAME Stent effective for patients undergoing angioplasty of SVG

John Muir Health opens The Hofmann Family Patient Care Tower

Novel heart attack treatment results presented at premier USA cardiology forum

Medtronic Eureka medical technology innovation portal launched

Job strain can increase risk of cardiovascular disease in women

People with anxiety disorders require additional cardiac test: Study

Hospitals need to work more to prevent heart attack deaths: Study

Angiotech reports $59.0 million total revenue for third quarter 2010

Pervasis receives $920,000 in grants under QTDP program

Novel drug-coated balloon technology adopted in niche applications across Europe: MRG

Loyola University surgeon uses new technique to reopen blockages in coronary arteries

IDEV receives FDA marketing clearance for SUPERA VERITAS Transhepatic Biliary System

CYP2C19 gene variant can increase risk of cardiovascular events in patients treated with clopidogrel

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News